[Pharmacoeconomic analysis of using mirabegron to treat overactive bladder in the setting of the Russian Federation health care].

Relevance: The present paper presents, for the first time in Russia, a comparative pharmacoeconomic analysis of using mirabegron (Betmiga) to treat overactive bladder (OAB).

Materials And Methods: Three medical technologies were evaluated: treatment of OAB with mirabegron 50 mg/day, solifenacin 5 mg/day and solifenacin 10 mg/day. In addition, the strategies of mirabegron and botulinum toxin type A were analyzed as a result of simulating the second-line treatment.

A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption.

Objectives: Infections that are inadequately treated owing to acquired bacterial resistance are a leading cause of mortality. Rates of multidrug-resistant bacteria are rising, resulting in increased antibiotic failures and worsening patient outcomes. Mathematical modelling makes it possible to predict the future spread of bacterial antimicrobial resistance.